BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Corixa’s Bexxar ODAC Hearing Delayed While FDA Sorts Data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Corixa’s Bexxar ODAC Hearing Delayed While FDA Sorts Data
Jan. 11, 2002
By
Kim Coghill
No Comments
Despite reassurances from Corixa Corp. that there s nothing wrong with its lead drug candidate, Bexxar, the Seattle company s stock tumbled Thursday on news that the FDA has delayed an application hearing for the product.
BioWorld